For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Eutilex Co., Ltd.

USPTO Granted Patents = 20

EPO Patents = 1

Trademarks = 7

Forward Citations = 34

Loading Chart...

Loading Chart...

46 inventors (with patents filed for the assignee):

Byoung S Kwon (20 out of 26 patents)

Young Ho Kim (8 out of 87 patents)

Seoung-Joo Lee (6 out of 6 patents)

4. Ho-Sik Oh (6 out of 7 patents)

5. Joong Won Lee (6 out of 6 patents)

6. Seung-Joo Lee (4 out of 4 patents)

7. Sun Woo Im (4 out of 5 patents)

8. Hyun Tae Son (4 out of 5 patents)

9. Kwang-Hui Kim (4 out of 5 patents)

10. Don-Gil Lee (4 out of 5 patents)

11. Beom-Kyu Choi (4 out of 5 patents)

12. Kwang Hee Kim (3 out of 21 patents)

13. Insoo Park (3 out of 4 patents)

14. Chungyong Han (3 out of 3 patents)

15. Young-Ho Kim (3 out of 115 patents)

20 patents: Sort by Forward Citations

1. 12331116 - Bispecific epitope binding protein comprising anti-4-1BB antibody and a PD-1 protein or fragments thereof and use thereof (2025-06-17),

2. 12122845 - Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof (2024-10-22),

3. 11951130 - Chimeric antigen receptor that binds HLA-DR and CAR-T cell (2024-04-09),

4. 11859004 - Anti-human 4-1BB antibodies and uses thereof (2024-01-02),

5. 11396555 - Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof (2022-07-26),

6. 11395836 - Cancer antigen specific cytotoxic T cell (2022-07-26),

7. 11072646 - Epitope for switching to T1 cell and use thereof (2021-07-27),

8. 11053298 - Epitope for switching to T2 cell and use thereof (2021-07-06),

9. 11013765 - Chimeric antigen receptor that binds HLA-DR and CAR-T cell (2021-05-25),

10. 10927183 - Anti-human VSIG4 antibodies and uses thereof (2021-02-23),

11. 10919976 - IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof (2021-02-16),

12. 10919972 - Anti-human 4-1BB antibodies and uses thereof (2021-02-16),

13. 10851151 - Epitope for switching to T17 cell and use thereof (2020-12-01),

14. 10774151 - Anti-human 4-1BB antibodies and uses thereof (2020-09-15),

15. 10626183 - IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof (2020-04-21),

Eutilex Co., Ltd. is a cutting-edge biotechnology company specializing in the development of innovative cancer therapies. Our mission is to transform the way cancer is treated by leveraging our expertise in precision medicine, immunotherapies, and targeted drug delivery. Using the latest advancements in molecular biology, genomics, and computational biology, we are committed to identifying novel pathways for cancer treatment and designing effective therapies. At Eutilex, we strive to make a significant impact on patients' lives through pioneering research, development, and commercialization of groundbreaking cancer treatments.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

20 Patents

#190 in Seoul

#610 in South Korea

#30,351 in the World

Seoul, South Korea

Eutilex Co., Ltd.

Forward Citations = 34

46 inventors:

Byoung S Kwon (20 out of 26 patents)

Young Ho Kim (8 out of 87 patents)

Seoung-Joo Lee (6 out of 6 patents)

4. Ho-Sik Oh (6 out of 7 patents)

5. Joong Won Lee (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…